| Bioactivity | Elaiophylin (Azalomycin B; Gopalamicin; Efomycin E) is an autophagy inhibitor, exerts antitumor activity as a single agent in ovarian cancer cells[1]. | |||||||||
| Invitro | Elaiophylin-mediated autophagy inhibition and lysosomal dysfunction affect ovarian cancer cell survival during hypoxia. Exposure to Elaiophylin (0.025-0.5 μM; 24 hours) causes a significant increase in ovarian cancer SKOV3 cell death in hypoxia conditions[1]. In both the SKOV3 and A2780 cell lines, Elaiophylin (0.25, 0.5, 0.75 μM; 24 hours) treatment leads to significant activation of cleaved CASP9/caspase-9 and PARP1 and downregulation of BIRC5/survivin in a concentration-dependent manner[1]. Cell Viability Assay[1] Cell Line: | |||||||||
| Name | Elaiophylin | |||||||||
| CAS | 37318-06-2 | |||||||||
| Formula | C54H88O18 | |||||||||
| Molar Mass | 1025.27 | |||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | |||||||||
| Storage |
|
Elaiophylin
CAS: 37318-06-2 F: C54H88O18 W: 1025.27
Elaiophylin (Azalomycin B; Gopalamicin; Efomycin E) is an autophagy inhibitor, exerts antitumor activity as a single age
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.